Peck Ronald
Known title: Chief Medical OfficerCIK: 0001783868
Associated companies
Transaction History
| ARVN | ▼ Sell | Open Market | 1,699 | $80K | 2/23/2024 | View on chart |
| ARVN | ▲ Buy | Grant | 39,250 | $0 | 2/23/2024 | View on chart |
| ARVN | ▲ Buy | Option Exercise | 4,010 | — | 8/11/2023 | View on chart |
| ARVN | ▼ Sell | Open Market | 1,324 | $32K | 8/11/2023 | View on chart |
| ARVN | ▲ Buy | Grant | 19,125 | $0 | 2/22/2023 | View on chart |
| ARVN | ▲ Buy | Option Exercise | 4,010 | — | 8/12/2022 | View on chart |
| ARVN | ▼ Sell | Open Market | 1,258 | $87K | 8/12/2022 | View on chart |
| ARVN | ▼ Sell | Open Market | 8,629 | $699K | 12/30/2021 | View on chart |
| ARVN | ▲ Buy | Option Exercise | 14,375 | $681K | 12/30/2021 | View on chart |
| ARVN | ▲ Buy | Option Exercise | 5,625 | $150K | 12/30/2021 | View on chart |
| ARVN | ▼ Sell | Open Market | 11,371 | $914K | 12/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Arvinas Releases Q2 2026 Earnings Call Transcript
Arvinas has published the transcript of its Q2 2026 earnings call. The document contains the company's financial results, guidance, and management commentary. Investors can use the transcript to assess the company's recent performance and future outlook.
Arvinas Releases Q2 2026 Earnings Call Transcript. Arvinas has published the transcript of its Q2 2026 earnings call. The document contains the company's financial results, guidance, and management commentary. Investors can use the transcript to assess the company's recent performance and future outlook.